{"name":"Epizyme, Inc.","slug":"epizyme-inc","ticker":"","exchange":"","domain":"epizyme.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2020-01-01","label":"Tazverik first approved","drug":"Tazverik","drugSlug":"tazemetostat","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Tazverik first approved","drug":"Tazverik","drugSlug":"chembl-chembl3414621","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Tazverik","genericName":"tazemetostat","slug":"tazemetostat","indication":"Epithelioid Sarcoma","status":"marketed"},{"name":"Tazverik","genericName":"TAZEMETOSTAT","slug":"chembl-chembl3414621","indication":"Epithelioid sarcoma","status":"marketed"}]}],"pipeline":[{"name":"Tazverik","genericName":"tazemetostat","slug":"tazemetostat","phase":"marketed","mechanism":"Tazverik works by blocking the action of the EED protein, which is involved in the regulation of gene expression.","indications":["Epithelioid Sarcoma","Relapsed or Refractory Follicular Lymphoma with EZH2 Mutation","Relapsed or Refractory Follicular Lymphoma without Satisfactory Alternatives"],"catalyst":""},{"name":"Tazverik","genericName":"TAZEMETOSTAT","slug":"chembl-chembl3414621","phase":"marketed","mechanism":"Tazverik works by blocking the action of an enzyme called EED, which is involved in the production of proteins that promote cancer growth.","indications":["Epithelioid sarcoma","Follicular lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPOWJjTDNFVVRTQXZ1N0d1NEpBZ29jS1dRc2MxTlU4OXRvV2hkYXhPUlBLYnVxc2J1ZDljWGZ1eU5OdTRlNjZUM1NaY1gwVmJhY1JSS0sxVWZnRHFCR2FzaVhJWnlhX2dseFpMZTJ5NkY4cDZlbnA0aE5fOTg1MlNfQmFaRjF4cGNVY3p4eV9LWDJMbjhJVG1IX0hFQngzUjFkdEljUkw1U0h5T1FPU3RJQWl5Y25MczRkOWxj0gFyQVVfeXFMTmsxOWR1UmdhVmI2ZHpBSmc4dmZ2ZWp3QVpTZ0hvci1QZmtGUHpQeV9xRjhQUGlBQ2tVTVZKRjVMWC13a0ZBQ3NWZUg2aUI0RW9FVFFyY0Rja2hHX2daN0dtRlQ4SDRuNGVrSFRRNGdsOWZB?oc=5","date":"2026-03-24","type":"pipeline","source":"Law360","summary":"Fired Ipsen Director Accuses The Pharmaceutical Co. Of Bias - Law360","headline":"Fired Ipsen Director Accuses The Pharmaceutical Co. Of Bias - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBNdnh0TEFuNFE3Z1JEUjdmQURDVlRpSC1tOHpYQnAzTkllaEF1S0JfMFlkbkM3NkJoV0pvNmpVX3JnbnJ5ZjEwRUs5X2xiaGktQndzVklsdkMxZDVfbkpYNG5QREJnQ1prZ0JiUGNEVlBSMUxpV21McWRzYw?oc=5","date":"2024-11-12","type":"trial","source":"Wiley","summary":"A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib - Wiley","headline":"A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients wi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxPck9NTElVdmhWaURzVzlXTzNGakpPZkNDTV9pZ1VzOUF1anVEbmtybGdWRHZhSTBqV3AwMmZZN1ctOW5BeGFnalhtYkZ2eFoxd0RsMloyaVROaHFjRThCR0ljdDl1aUEtQkowTlJpTHV2R1pLYTZqNjFjZnZWRFlPSURiWWFKWE45TmxtSjVkZkdHUGw5a3M0ZVB5QnM4ZkZxR2FFekhFQU55b3FHa1ljNnU3RkxhT2FYRUlKUFlQbFBiUmVxSGJ1NVh0azZhcGpH?oc=5","date":"2024-09-10","type":"pipeline","source":"Reuters","summary":"Employee of French drugmaker Ipsen to plead guilty to US insider trading - Reuters","headline":"Employee of French drugmaker Ipsen to plead guilty to US insider trading","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQdDBKU25VaVlxQ2g3SUdvMV9HNGQ5VnNRRnp4OWstT1lXdmdtNmVMME1aenNQNGtYTDhPQkxMTHdIZW5RNUlTaTV3bHVSc2VudThtVW1BSjVVNzFNMUN2MEJra0FSQnlDRHUwMThhbnFXUFN4V0hRZEtDclNkX3JNQkNEUlJPa0V0aEFNdGpneGNXcENJbnc?oc=5","date":"2023-05-17","type":"pipeline","source":"Yahoo Finance","summary":"Ipsen completes acquisition of Epizyme expanding its portfolio in oncology - Yahoo Finance","headline":"Ipsen completes acquisition of Epizyme expanding its portfolio in oncology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQam1XTFBqLUowNUNrVUxBbW5oYlFHcUFTSXdmcm9wZ0g0dUNReVpwX0ZPVjlwcm4xSDR6N3FGaTcySXpJY0xEZkJoQjFkTnBhNWVDZ21EOTMzRXhpYVlYMlY5eXV6eVRZLUZLODVQNFRJREFkUG9Scm5nS081Q09UeDBHMnNTbVR6T1Vtbk5pdE5IVi1vWjlrb1pOcEgzMWFIbHR2NkZQMUFTT25panVWbVJDQzN0VmM?oc=5","date":"2022-08-05","type":"patent","source":"Ipsen","summary":"Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022 - Ipsen","headline":"Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPZkd4bHVZNW1HblV3N0FuODdjNE9iNTUzZHhFa1hHaVBxS3BGOE92U1hERll6Njl5MUZFMVJ1VlVnb0s1NUItX19Ndm9VcmlMWDhWVDl2cDBaUWFmN0E0WUUtdVJZLTFNZ0Z6VkJyQ0tUVnMzNWhZTU9xbEpxNnpna3VsamhMWjIwSFdSZGFKdE8xS2Q0aEVTMFlpMk9fa1pTVENuUw?oc=5","date":"2022-07-13","type":"pipeline","source":"Fierce Pharma","summary":"Epizyme SEC filing details its desperate days in free fall before $247M sale to Ipsen - Fierce Pharma","headline":"Epizyme SEC filing details its desperate days in free fall before $247M sale to Ipsen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPWWtjSHJXSjVrTHlfSUZMZC1XUFNnNUNhaUpzb0pxdFllazlUZmZqVHJrYVZMb0NrX3dWTDc4Zk96NHdmcnBSemd6d1hEbXFFb2d5ZDVDc19xTlQxVVBzaHQzbTZIT3FJcFpZWjcxZTIwSWJKb21ocV91VVVkMmYtMHpOWlRvNlRCUlh1R3JmeE1KaFdmRWluSXlpLS1OQQ?oc=5","date":"2022-06-27","type":"deal","source":"Ipsen","summary":"Ipsen to Acquire Epizyme - Growth in Oncology | Ipsen Global - Ipsen","headline":"Ipsen to Acquire Epizyme - Growth in Oncology | Ipsen Global","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQOUZaWWtDWFpnZlRuczBaQmZ5V1dqcmN3MUJkVUpST2JUbGZTVDhDa0JVTlVqS2hDUE50ZThSYkRuTlF2ajd2ajJ3TDE2NVZYQ2Y0YzFTSVdRWTRpcm9janJDaDIxZTNSTmxJeVVZOVBZWWptZ2VtYm5ZWGtLcWhVUW50T25xdHZWRE13OXdLVnoxb1hqbWtObWVhU01XQQ?oc=5","date":"2022-06-27","type":"deal","source":"BioPharma Dive","summary":"Ipsen adds to cancer business with bargain buyout of Epizyme - BioPharma Dive","headline":"Ipsen adds to cancer business with bargain buyout of Epizyme","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNQlNhMUh3QzE2ekNyMVJOdUhuQXU3enRlaWdGSGFXUjNrNS1Kd1RfZ2JNd3VTaXlHYlkyejRsU0U2SEV1QlJOM3ZOeHJjSTU1a05xZlJhblhLZldlYzg5Sm10QTRfVmExaWZWdi1OZ2UtMEZteU1ta25CWGl5bTMzTGloSmF4dlRxSDlJQ2gycTNUVF9pSlNyVTFmUkRVNGVFUk85VllCRnQ0ZHdUOXpjVk1zVmRkY0JYR3JJUTFzTDRiZw?oc=5","date":"2022-06-27","type":"deal","source":"Fierce Pharma","summary":"Still wheeling and dealing, Ipsen acquires Epizyme and lymphoma drug Tazverik for $247M - Fierce Pharma","headline":"Still wheeling and dealing, Ipsen acquires Epizyme and lymphoma drug Tazverik for $247M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPZ2JackZBbllHXzIteDRERE1yME9OeGgtY0k4QlFWS0l3ajBWOVh1QjExbHdNWmhXZEcyd0xRMjZPSWdSZlZMRW04M09KVDQzX0pmbm1COENoQi1XUFlxV1Q5UXNQYWdJd0trLUVackNnTmR6RUMxRXhsTXNIN1pERi1SVThPMWluTXFfdnRZRzhOV2ZoV1RPVzRSY010U2V3a0M1eEczRDNLdTE2T3c?oc=5","date":"2022-06-27","type":"regulatory","source":"MedCity News","summary":"Ipsen’s $247M Epizyme acquisition brings approved cancer drug & more in pipeline - MedCity News","headline":"Ipsen’s $247M Epizyme acquisition brings approved cancer drug & more in pipeline","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQcDU2TDJYZnBmdXlrSkp3U1lycmtsMzVCZ2llTUtkR0xtaXQzYVU1X0x6bHZ0bUpuWnZPZUM2UmVQMW4tcjJiRkNGZkJKN0lpVVFtemdzU0dTU2ZWQS0xODdZVXdFNTRzcmczM0V0bTlyZlV1eVFUMGlEa2VranVDcUNKYXVCNGtQTmd2cVo3OA?oc=5","date":"2021-07-21","type":"pipeline","source":"drugdiscoverytrends.com","summary":"34 of the most innovative pharmaceutical products - drugdiscoverytrends.com","headline":"34 of the most innovative pharmaceutical products","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxOaWN5ZFdzbC1QQU4xbUVRNDc0ZEJ0RnNCc2hoRWV3TVlYLTU5NXBxQ29QWmVfOEltOFVOVzUwNEtLSGZjZDA5LXp4N3V4VFVRSmtnS2x4aUNuRTQ4dEtnZFJWLXFjQWtYQjJBZmNuMzM1UWdCZjhfWGVYRDB2QndsMmRpRW5KVVQ5QjNDMnc5VGw2S0dTMXktaUV0Q25XZDJLQ3A0VEdHSlB2S2hLNm1xSFBMcUx2QUFjY1FEYjNtOG52eVRhZHRCTlZNMkdaU2ZiSHBEdTlubFNUa1FTQkx3TEU0MGVLOEph?oc=5","date":"2020-02-24","type":"earnings","source":"businesswire.com","summary":"Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results - businesswire.com","headline":"Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}